Skip to main content
padlock icon - secure page this page is secure

In Vivo Tumor Secretion Probing Via Ultrafiltration and Tissue Chamber:Implication for Anti-Cancer Drugs Targeting Secretome

Buy Article:

$63.00 + tax (Refund Policy)

Tumor secreted proteins/peptides (tumor secretome) act as mediators of tumor-host communication in the tumor microenvironment. Therefore, development of anti-cancer drugs targeting secretome may effectively control tumor progression. Novel techniques including a capillary ultrafiltration (CUF) probe and a dermis-based cell-trapped system (DBCTS) linked to a tissue chamber were utilized to sample in vivo secretome from tumor masses and microenvironments. The CUF probe and tissue chamber were evaluated in the context of in vivo secretome sampling. Both techniques have been successfully integrated with mass spectrometry for secretome identification. A secretome containing multiple proteins and peptides can be analyzed by NanoLC-LTQ mass spectrometry, which is specially suited to identifying proteins in a complex mixture. In the future, the establishment of comprehensive proteomes of various host and tumor cells, as well as plasma will help in distinguishing the cellular sources of secretome. Many detection methods have been patented regarding probes and peptide used for identification of tumors.





No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Tumor secretion; drugs; mass spectrometry; secretome; tissue chamber; ultrafiltration

Document Type: Research Article

Publication date: 01 January 2008

More about this publication?
  • Recent Patents on Anti-Cancer Drug Discovery publishes review articles on recent patents in the field of anti-cancer drug discovery e.g. novel bioactive compounds, analogs & targets. A selection of important and recent patents on anti-cancer drug discovery is also included in the journal. The journal is essential reading for all researchers involved in anti-cancer drug design and discovery.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more